Format

Send to

Choose Destination
Obstet Gynecol Clin North Am. 2018 Sep;45(3):495-509. doi: 10.1016/j.ogc.2018.04.010.

Management of Attention Deficit Hyperactivity Disorder During Pregnancy.

Author information

1
Perinatal and Reproductive Psychiatry Program, Harvard Medical School, Massachusetts General Hospital, 185 Cambridge Street, 2nd Floor, Boston, MA 02114, USA. Electronic address: asbaker@mgh.harvard.edu.
2
Perinatal and Reproductive Psychiatry Program, Harvard Medical School, CTNI, Women's Mental Health, Massachusetts General Hospital, 185 Cambridge Street, 2nd Floor, Boston, MA 02114, USA.

Abstract

Attention deficit hyperactivity disorder (ADHD) is a common neurobehavioral disorder affecting 3.2% of women. More women are taking psychostimulant medications, including during pregnancy. Although stimulant use does not appear to be associated with congenital malformations, there are inconsistent data about other obstetric risks, and no long-term neurodevelopmental data exist to inform clinical management decisions. This article summarizes the available data regarding perinatal exposure to psychostimulants. It also highlights the importance of the risk-risk analysis for clinicians and patients to consider, weighing risks of medication exposure to risks of ADHD during pregnancy, including driving safety and major impairment in occupational roles.

KEYWORDS:

Amphetamines; Attention deficit hyperactivity disorder; Methylphenidate; Pregnancy

PMID:
30092924
DOI:
10.1016/j.ogc.2018.04.010
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center